Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of YHB1411-2 in Healthy Male Volunteers

Rheumatic Arthritis Clinical Trial

Official title:
A Block-randomized, Double-blind, Placebo-controlled, Single-dose Escalating, Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of YHB1411-2 in Healthy Male Volunteers

Status Completed

Clinical Trial Summary

A block-randomized, double-blind, placebo-controlled, single-dose escalating, phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics of YHB1411-2 in healthy male volunteers

Clinical Trial Description

First in human Study ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01525147
Study type	Interventional
Source	Yuhan Corporation
Contact
Status	Completed
Phase	Phase 1
Start date	December 2011
Completion date	November 2013

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03685110` - CoreHip - Post Market Clinical Follow-Up Study
Recruiting	`NCT04485325` - Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA Patients	Phase 4
Not yet recruiting	`NCT02020668` - Efficacy of Physiotherapy on the Health and Quality of Life of the Rheumatic Patient	Phase 2
Recruiting	`NCT05007340` - ILD-SARDs Registry and Biorepository
Completed	`NCT05291130` - AESCULAP® Plasmafit® Cementless Acetabular System With Vitelene® Vitamin E Stabilized Highly Crosslinked Polyethylene
Active, not recruiting	`NCT04255966` - Plasmafit® Revision Structan® Hip Endoprosthesis Cup